Table 1 Neutralization of SARS-CoV-2 Omicron variant by commercially developed monoclonal antibodies and the class 4 Ab-3467
mAb | Developer | IC50 (ng ml−1) | ||
|---|---|---|---|---|
Ancestral (A.2.2) | Omicron (B.1.1.529)1 | Fold change | ||
Sotrovimab | Vir Biotechnology / GSK | 372 | 1,059 | 2.8 |
Casirivimab | Regeneron | 27 | nn (to 10 µg ml−1) | N/A |
Imdevimab | Regeneron | 25 | nn (to 10 µg ml−1) | N/A |
Bamlanivimab | AbCellera Biologics / Eli Lilly | 32 | nn (to 10 µg ml−1) | N/A |
Cilgavimab | Astra Zeneca | 18 | nn (to 10 µg ml−1) | N/A |
Tixagevimab | Astra Zeneca | 47 | 3,490 | 73.8 |
AB-3467 | Burnett et al.48 | 502 | nn (to 10 µg ml−1) | N/A |
